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Abstract 
Purpose: Several common genetic variants (single nucleotide polymorphisms, 
SNPs) have been shown to be associated with breast cancer (BC) risk in the general 
population, and to modify BC risk for BRCA1 and BRCA2 mutation carriers. Co-localization 
of variable number of tandem repeats (VNTR) with these BC-associated SNPS has not been 
comprehensively studied.  
Methods: Cross referencing of genome-wide VNTR with the known BC genome-
wide association studies (GWAS) SNPs significantly associated with increased risk for 
developing breast cancer was carried out. Analysis was based on the overlap between the 
VNTR and 10-kb windows around these BC-susceptibility SNPs. 
Results: Cross referencing of the 1.2 million TR with the 161 known BC- associated 
SNPs in the general population led to 690 matches. Of those, in 17 VNTRs, the SNP was 
within the VNTR. Analysis restricted to loci known to modify BC penetrance in BRCA1 
(n=31) and BRCA2 (n=33) mutation carriers led to 139 and 170 co-localization matches, 
respectively. For these, none of the SNPs were within the VNTR. The distances between the 
SNPs and the VNTRs were not significantly different from what was expected to occur by 
chance alone (p=0.61; p=0.44; p=0.25, respectively).  
Conclusion: There is no evidence that VNTRs co-localize with currently reported 
SNP tagged BC GWAS loci. 
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Introduction 
Several genetic variants that contribute to breast cancer (BC) susceptibility have 
been identified, with BRCA1 and BRCA2 being the predominant, clinically relevant genes 
[1]. In some families exhibiting familial aggregation of BC, BC is diagnosed at earlier age 
with each successive generation [2]. This phenomenon has largely been attributed to a birth 
cohort effect [3]. However, it is plausible that these observed successive generational 
younger ages at diagnosis may reflect a genetic-based phenomenon called anticipation. 
Anticipation, predominantly noted in neurodegenerative disorders, implies that there are 
dynamic mutations particularly affecting trinucleotide repeats expansion that impact the 
phenotype and age at diagnosis [4]. Previous studies reported that in some cases, 
anticipation can clinically be defined in subset of familial BC cases [2], yet not all studies 
concur [5]. Furthermore, a similar, anticipation-compatible phenomenon has been reported 
in some families carrying mutant BRCA1/2 alleles [2, 6]. While BRCA1/2 germline mutation 
carriers are at significantly increased risk for developing breast and/or ovarian cancer, 
penetrance is incomplete [7]. Combined with the variable age at diagnosis of identical 
mutation carriers, incomplete penetrance is suggestive of the existence of modifier factors- 
genetic and environmental [8]. Several single nucleotide polymorphisms (SNPs) have been 
shown to be associated with breast or ovarian cancer risks in BRCA1 and BRCA2 mutation 
carriers (http://apps.ccge.medschl.cam.ac.uk/consortia/cimba//). Although the risk 
associated with individual variants is low, in combination they can result to large differences 
in absolute risk for mutation carriers with implications for risk management [9].  
In the human genome, repetitive sequences comprise approximately half of the 
genome. Tandem repeats are subsets of these repetitive sequences and while the majority of 
tandem repeats are monomorphic, some are polymorphic, known as variable number of 
tandem repeats (VNTRs). The association of VNTRs and BC risk in the average risk 
population and as modifiers of BRCA1/2 gene mutations has previously been reported in the 
context of “candidate genes” [e.g., 10].  However, studies at a genome-wide scale are 
relatively scarce. In this study, we are investigating the co-localization of VNTRs with 
significantly-associated signals for BC risk. 
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Methods 
 
The Tandem Repeat database (TRDB- https://tandem.bu.edu/cgi-bin/trdb/trdb.exe?taskid=0) 
was accessed. This database contains nearly 1.2 million tandem repeats. SNPs that have 
reached a significance level of p < 5e-08 were considered for the general population [11] 
SNPs that were previously reported to be associated with BC risk for BRCA1/2 mutation 
carriers (“modifiers”) [12] were separately analyzed. A SNP was considered as a risk 
modifier in BRCA1/2x mutation carriers if (1): statistical significance was reached for the 
general population (p < 5e-08) as was previously described [9] and the BRCA1/2 carriers (p 
< 0.05), and (2): the effects estimated for these two populations were in the same direction. 
The resulting three SNP sets (general population, BRCA1 carriers, and BRCA2 carriers) 
were cross- referenced with the TRDB. The sum of the distances between SNPs and 
VNTRs, denoted as D0, was calculated for the 10kb-windows around SNPs. A resampling 
method similar to the local annotation shifting procedure [13] was used to assess whether 
there were significantly more VNTRs in the vicinity of the known BC susceptibility SNPs, 
by approximating the null distribution of the distances. Briefly, this involves repeating the 
following algorithm 10,000 times: (I) shifting all the VNTRs by  base pairs from their 
initial position, where  is a random integer between 1 and 10,000; (II) computing Db, the 
sum of the distances for the shifted pattern of co-localization. The p-value for the test of co-
localization was then set equal to the proportions of Db’s exceeding D0. Mapping of the 
resulting SNPs and tandem repeats to the nearest genes was extracted from Michailidou et 
al.  2017[11] and Milne et al 2017 [12]. 
 
Results 
General population- Overall, 161 SNPs that showed a significant association with BC risk for 
the general population were used for cross referencing. One hundred and forty six SNPs 
showed matching with at least one VNTR, with a total of 676 unique matching VNTRs (see 
Table 1 and supplementary table 1A and 1B). However, the pattern of co-localization was not 
significant (p=0.61). In 17 of the matches, the SNP was within the VNTR and in 5 matches, 
the SNP was within a tandem repeat of the Short Tandem Repeats in Regulatory Regions 
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Table (STaRRRT) (14). The size of the “unique” 676 TRs identified varied between 25 and 
2713 base pairs, with a median of 46.5 base-pairs. 
 
BRCA1 mutation carriers- Overall, in the CIMBA data base and using the oncoarray data, 31 
SNPs that showed a significant association with BC risk for BRCA1 mutation carriers were 
included. Twenty-eight SNPs showed matching with at least one VNTR, with a total of 139 
unique matching VNTRs (Table 1 and supplementary table 2A and 2B). However, the pattern 
of co-localization was not significant (p=0.44). No SNPs were within the VNTR. The size of 
the unique 139 VNTRs identified varied between 25 and 2713 base-pairs with a median of 55 
base-pairs. 
 
BRCA2 mutation carriers- Overall, 33 SNPs that showed a significant association with BC 
risk for BRCA2 mutation carriers, derived from the same sources as for BRCA1, were 
included. Thirty-two SNPs showed matching with at least one VNTR with a total of 158 
unique matching VNTRs (Table 1 and supplementary table 23 and 3B). However, the pattern 
of co-localization was not significant (p=0.25). No SNPs were within the VNTR. The size of 
the unique 158 VNTRs identified varies between 25 and 2713 base-pairs with a median of 48 
base-pairs. 
 
Discussion 
 
The present study investigated co-localization of VNTRs with the most significantly 
associated SNP in each region that exhibited genome-wide significance levels, and no 
statistically significant co-localization was found between VNTRs and SNPs associated with 
BC risk or SNPs associated with BC risk modification for BRCA1 or BRCA2 mutation 
carriers.  These bioinformatics findings reduce the likelihood that VNTRs are involved in 
BC susceptibility or in modifying BRCA penetrance that can be tagged by SNPs identified 
through GWAS. However, because these SNPs do not necessarily represent the causal or the 
key “functional” variants at each locus, a more informative approach would be to investigate 
the set of all candidate causal SNPs in each region (“credible” set of variants); these data are 
not currently available for all the known BC susceptibility and risk loci. It is also possible 
that VNTRs play a role in BC predisposition but a GWAS design cannot identify VNTRs of 
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risk; not all VNTRs will be “tagged” by SNPs.  Secondly, they may play a role through 
epigenetic changes that primarily affect VNTR, similar to what has been reported in 
neurodegenerative diseases with “dynamic mutations” [15]. These results do not rule out 
such effects.  Further investigation to elucidate the role if any that VNTR play in BC 
susceptibility is needed.   
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Table 1. Matches between tandem repeats and significant SNPs for breast cancer among the general 
population, BRCA1 and BRCA2 mutation carriers 
 
  General population BRCA1 mutation carriers BRCA2 mutation carriers 
Chr noTr noSnp Match SnpIn TrIn noSnp Match SnpIn TrIn noSnp Match SnpIn TrIn 
1 93640 16 69 14 69 4 17 4 17 4 13 4 13 
2 93062 12 44 10 44 3 11 2 11 0 0 0 0 
3 72794 10 32 10 32 0 0 0 0 2 11 2 11 
4 72412 6 23 6 23 0 0 0 0 0 0 0 0 
5 67737 16 77 14 77 3 17 3 17 4 23 4 23 
6 65490 10 43 9 43 4 20 3 20 4 25 4 25 
7 68593 8 28 6 28 1 2 1 2 0 0 0 0 
8 57450 10 45 10 45 3 12 3 12 0 0 0 0 
9 49378 8 28 8 26 1 2 1 2 0 0 0 0 
10 55629 11 49 10 37 1 5 1 5 5 32 5 20 
11 51145 6 41 6 41 2 13 2 13 3 16 3 16 
12 55355 6 32 5 32 2 18 2 18 2 10 2 10 
13 38032 2 4 2 4 1 2 1 2 0 0 0 0 
14 35004 6 24 5 24 0 0 0 0 0 0 0 0 
15 32212 1 3 1 3 0 0 0 0 0 0 0 0 
16 41932 7 24 6 24 3 8 2 8 2 8 2 8 
17 39419 5 20 5 20 0 0 0 0 2 6 2 6 
18 29706 4 14 4 14 1 2 1 2 1 2 1 2 
19 37498 7 44 7 44 1 9 1 9 1 5 1 5 
20 27704 2 2 1 2 0 0 0 0 1 8 1 8 
21 18086 1 0 0 0 0 0 0 0 1 0 0 0 
22 19700 7 44 7 44 1 1 1 1 1 11 1 11 
TOT 1121978 161 690 146 676 31 139 28 139 33 170 32 158 
 
Legend- Chr = chromosome; noTr = number of TRs; noSnp = number of genome-wide significant 
SNPs; Match = number of matches between TRs and SNPs; SnpIn = number of 10kb-windows 
overlapping at least one TR; TrIn = number of TRs overlapping at least one 10kb-window. 
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Supplementary tables 
 
General- Each table contains the following columns for the matches identified from the previously 
reported SNPs: 
 
idSNP: SNP ID 
Chr: Chromosome 
staWin: Start position (Build 38) of the 10-kb window 
posSNP: Position of the significant SNP 
stoWin: Stop position of the 10-kb window 
prGenes: Proposed candidate genes 
idTR: Tandem repeat (TR) ID 
staTR: Start position (Build 38) of the TR 
stoTR:  Stop position of the TR 
lenPat: Size of the consensus pattern 
noCop: Number of copies aligned with the consensus pattern 
lenTR:  Size of the TR 
Pattern: Consensus pattern 
 
 
 
Supplementary table 1A- Tandem repeats that co-localize to GWAS significant SNPs in the 
general population  
 
Supplementary table 2A- Tandem repeats that co-localize to GWAS significant SNPs in BRCA1 
mutation carriers  
 
Supplementary table 3A- Tandem repeats that co-localize to GWAS significant SNPs in BRCA2 
mutation carriers  
 
Supplementary table 1B- Significant SNP’s in BC GWAS in the general population 
 
Supplementary table 2B- Significant SNP’s in BC GWAS in BRCA1 mutation carriers 
 
Supplementary table 3B- Significant SNP’s in BC GWAS in BRCA2 mutation carriers 
